Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec 4:6:2050312118816919.
doi: 10.1177/2050312118816919. eCollection 2018.

HIV virologic response better with single-tablet once daily regimens compared to multiple-tablet daily regimens

Shashi N Kapadia  1 , Robert R Grant  2 , Susan B German  3 , Baljinder Singh  2 , Amy L Davidow  4 , Shobha Swaminathan  5 , Sally Hodder  6
Affiliations

HIV virologic response better with single-tablet once daily regimens compared to multiple-tablet daily regimens

Shashi N Kapadia et al. SAGE Open Med. .

Abstract

Background: Single-tablet regimens are preferred prescription choices for HIV treatment, but there are limited outcomes data comparing single-tablet regimens to multiple-tablet regimens.

Methods: We retrospectively assessed treatment-naïve patients at a single urban HIV clinic in the United States for viral load suppression at 6 and 12 months after initiating either single-tablet or multiple-tablet regimens. Multivariate regression was performed to obtain relative risks and adjust for potential confounders.

Results: Of 218 patients, 47% were on single-tablet regimens and 53% on multiple-tablet regimens; 77% of single-tablet regimen patients had undetectable viral load at 6 months compared to 61% of multiple-tablet regimen patients (p = 0.012). At 12 months, 82% on single-tablet regimens and 66% on multiple-tablet regimens (p = 0.019) had undetectable viral load. Relative risk of any detectable viral load was 1.6 (95% confidence interval: 1.1-2.5) for patients on multiple-tablet regimens compared to single-tablet regimens at 6 months, and 2.2 (95% confidence interval: 1.2-4.0) at 12 months.

Conclusion: Single-tablet regimens may provide better virologic control than multiple-tablet regimens in urban HIV-infected persons.

Keywords: HIV; antiretroviral therapy; fixed-dosed combinations; sexually transmitted infections; single-tablet regimens.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: S.S. has received grant support from Gilead Sciences and consulting fees from Viiv and Gilead Sciences. S.H. has received consulting fees from Bristol-Meyers Squibb, Gilead Sciences, Janssen Pharmaceuticals, and Viiv. Her spouse has received consulting fees from Johnson and Johnson and Inovia, and retains stock options from Merck.

Figures

Figure 1.
Figure 1.
Multiple-tablet regimen components. Atazanavir, darunavir, fosamprenavir, and lopinavir regimens included ritonavir for pharmacologic boosting. All regimens included dual nucleoside reverse transcriptase inhibitor backbone.
See this image and copyright information in PMC

References

    1. Panel on Antiretroviral Guidelines for Adults Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services, 2018, https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf
    1. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001; 15(9): 1181–1183. - PubMed
    1. Fielden SJ, Rusch ML, Yip B, et al. Nonadherence increases the risk of hospitalization among HIV-infected antiretroviral naive patients started on HAART. J Int Assoc Physicians AIDS Care 2008; 7(5): 238–244. - PubMed
    1. Kitahata MM, Reed SD, Dillingham PW, et al. Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death. Int J STD AIDS 2004; 15(12): 803–810. - PubMed
    1. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133(1): 21–30. - PubMed

LinkOut - more resources